The Cohere Beauty Strategy: Bridging The Gap Between Concept And Clinical Reality
Within this environment, Cohere Beauty plays a distinct role as a premier contract development and manufacturing organization (CDMO) and strategic innovation partner, supporting some of the industry’s most advanced skincare launches from formulation through scale. With a team of 15 degreed quality control chemists and engineers, 16 research and development (R&D) formulation scientists, two PhD scientists and decades of formulation expertise, Cohere Beauty has positioned itself at the forefront of the “skinflection point,” the threshold where true innovation is shifting from marketing-driven claims to science-backed products that prove efficacy and biomimetic delivery systems.
Cohere Beauty matters because it has effectively addressed three of the most crucial challenges brands face today:
- Navigating Skincare Innovation and Choosing the Right CDMO: Modern skincare has reached a level of complexity where clinical is no longer a luxury differentiator, but a nonnegotiable requirement for entry. As such, the challenge for brands isn’t just finding a unique and creative concept, but offering products with proven efficacy and an infrastructure capable of managing the scientific and regulatory hurdles of a post-Modernization of Cosmetics Regulation Act (MoCRA) world. Cohere Beauty delivers this by partnering as a strategic R&D extension rather than a traditional manufacturer. A Deep Dive on Ingredient and Category Trends: As consumer demand shifts toward skinification, biotech-driven actives and wellness-adjacent benefits, brands face growing pressure to make smarter, earlier R&D bets. The challenge is no longer identifying trends once they are established, but determining which ingredients, formats and claims have the technical and commercial potential to scale before they become ubiquitous. To address this, Cohere Beauty has built an internal Innovation Library designed to translate emerging science into formulation-ready concepts. Rather than reacting to market trends, the team continuously pre-develops product frameworks across ingredients, delivery systems and categories, informed by clinical data, ingredient sourcing and regulatory viability. For brands, this approach reduces uncertainty and compresses development timelines, enabling them to move directly into refinement and differentiation instead of navigating prolonged trial-and-error cycles. The Future of Skincare Innovation: Clinicals, AI and Innovation-First Brands: The industry is moving away from the growth-at-all-costs mindset toward a demand for both strong profit margins and efficacy. Today, credible testing and data-driven proof points are essential to win over retailers and investors. For the next generation of brands, the focus will be on how to accelerate speed to market without sacrificing the integrity of the results. Cohere Beauty is redefining this future by merging artificial intelligence with disciplined clinical standards. By leveraging AI platforms for predictive stability and formulation modeling while maintaining a strict four-to-five month clinical window, Cohere Beauty builds innovation-first brands rooted in proven performance and technical excellence.
In this white paper, the first of a three-part series, we have examined how Cohere Beauty is leveraging its technical infrastructure and R&D expertise to help brands navigate the intense scientific and regulatory hurdles of the modern skincare market. We look at Cohere Beauty’s perspective on how brands should assess CDMO partners in an increasingly technical and competitive landscape and the specific capabilities required to turn ambitious concepts into successful, clinical-grade launches. The second white paper will provide a deep dive into the evolving ingredient and category forces, from biotech-driven actives to wellness-adjacent launches, shaping tomorrow’s hero products. The third paper will explore the future of skincare innovation, focusing on the baseline necessity of clinical validation and the transformative role of artificial intelligence in formulation and brand building.
How Cohere Beauty is reshaping the industry through cutting-edge R&D and product concepts
Section 1: The New Innovation Standard
Beauty has reached an inflection point where incremental updates no longer drive differentiation, forcing brands to pursue deeper, more transformative forms of innovation to remain competitive. As Jami Mitchell, director of R&D at Cohere Beauty, says, “Innovation in skincare is shifting from marketing-driven claims to science-backed breakthroughs. We’re entering a period where true innovation will come from the convergence of advanced biotechnology, more sophisticated ingredients and a higher standard for clinical validation.”
Specifically, truly transformative innovation is being driven by the rise of next-generation peptides, postbiotic microbiome modulators, bioengineered delivery systems and mRNA-inspired actives that offer high performance without the trade-off of skin irritation. What used to be considered clinical will soon be just table stakes. Every brand, regardless of price point, will need robust, well-designed clinical studies to substantiate its claims as the industry moves away from loosely structured, supplier-driven protocols toward real-world performance data.
To bridge this gap, Cohere Beauty provides a strategic R&D partnership that goes beyond the scope of a standard contract manufacturer. While clinical testing is not conducted in-house, Cohere Beauty supports brands by leveraging raw material supplier data packages to substantiate ingredient-led performance and align formulas with appropriate claim language. For brands requiring higher-vigor validation, Cohere Beauty also maintains partnerships with independent clinical testing laboratories, connecting its customers with the right testing partner and protocol for their goals, ranging from basic consumer use studies and instrumental testing to robust clinical trials, to ensure finished-product claims meet the rigor that the market, retailers and consumers now expect.
Section 2: The Strategic R&D Partnership
Choosing a CDMO isn’t just about manufacturing; it’s about securing a long-lasting strategic partnership. Many brands underestimate the technical demands and sheer expense of innovation. Even before a single product ships, it can cost upwards of $25,000 or more to build one SKU, accounting for marketing spend, creative development, safety and stability testing, regulatory submissions, clinical studies and the operational lift needed to scale.
Cohere Beauty reinforces this partnership through:
- R&D Bench Depth: Cohere Beauty currently maintains a team of over 15 specialized chemists, including experts with years of “on bench” experience in skincare applications. These experts solve complex formulation issues and eliminate the technical gaps that can occur when brands lack in-house chemistry expertise. Regulatory Bandwidth: Cohere Beauty has doubled the size of its internal regulatory department to manage the massive operational lift required for global compliance and new standards like MoCRA. Predictive AI: Cohere Beauty utilizes AI-driven platforms to call out potential ingredient interactions early, speeding up time to market without sacrificing safety.
Step 3: Balancing Speed with Scientific Rigor
While speed-to-market is critical, innovation requires time, specifically for clinical validation.
What’s more, brands often overlook the risk of single-sourcing ingredient supplies for novel and trending actives, which can derail a launch if not strategically secured through a dual-source supply for reliability.
To bridge this gap, the Innovation Library allows brands to start creatively with textures and sensory profiles while knowing the underlying formulation is already technically sound and scalable. This library approach allows the team to take names out of it and help brands focus on textures, creative and crossover opportunities before they are predefined by a narrow category like hair, skin care or fragrance.
